Earlier this year, PriceWaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association noted in their joint annual MoneyTree Survey that Life Science companies (encompassing the biotechnology and medical device industries) continue to dominate the field when it comes to raising venture money, accounting for 27 percent of all venture capital dollars invested in 2004. In total, $5.6 billion was invested in 578 companies, the largest dollars and deals in four years.
The Life Science industry has come of age and now it's up to the emerging growth companies and the investment community to proceed aggressively, but with caution, to meet, and even exceed the promise of the field.
Our "Life Science" conference will bring entrepreneurs from emerging growth biotech, pharma and medical device companies together with investors - including venture capitalists, investment bankers and strategic partners/investors from the large pharma, biotech and medical device companies to discuss and debate the current challenges and opportunities facing the life sciences industry. The conference will include both panels and smaller roundtable sessions where attendees will have access to the distinguished speakers.